Characterization of the blast cell in childhood non-Hodgkin's lymphoproliferative malignancies

Peter Felix Coccia

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Studies of cytomorphology, cytochemistry, phagocytosis and surface membrane markers for T- and B-lymphocyte characteristics have led to the realization that the traditional separation of ALL and NHL is invalid. Patient characteristics, clinical presentation, distribution of disease at diagnosis, response to therapy, remission duration, sites of relapse and survival all appear to correlate better with characterization and classification by the type of blast cell identified rather than with presence or absence of bone marrow involvement at diagnosis. Clearly, leukemias and lymphomas with cytomorphologically and cytochemically distinctive Burkitt's tumor cells which have monoclonal IgM on their surface are the same disease. In addition many clinical similarities are present in these patients whether or not the bone marrow is involved. Likewise, patients with sheep erythrocyte positive blast cells have similar diseases whether or not the marrow is involved. Subtypes of surface marker negative ALL and NHL will certainly be defined when the studies described above are routinely performed. Morphologic and cytochemical subtypes are recognizable and studies with (T cell antigen) HTLA and HBLA antisera suggest that further subclassification is possible. Whether these differences will be clinically, prognostically, and therapeutically useful must await the test of time. Attempts to stage childhood ALL and NHL on the basis of expected prognosis will certainly benefit from the additional input of careful characterization of the blast cells in these disorders. Careful pretreatment staging of children with non-Hodgkin's lymphoproliferative malignancies will in the future lead to more specific and effective therapy and improved remission duration and survival. (111 references).

Original languageEnglish (US)
Pages (from-to)287-296
Number of pages10
JournalSeminars in Oncology
Volume4
Issue number3
StatePublished - Dec 1 1977

Fingerprint

Non-Hodgkin's Lymphoma
Bone Marrow
Neoplasms
Hospital Distribution Systems
Histocytochemistry
Burkitt Lymphoma
Survival
Viral Tumor Antigens
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Phagocytosis
Immunoglobulin M
Immune Sera
Lymphoma
Sheep
Leukemia
B-Lymphocytes
Erythrocytes
T-Lymphocytes
Recurrence
Membranes

ASJC Scopus subject areas

  • Oncology

Cite this

Characterization of the blast cell in childhood non-Hodgkin's lymphoproliferative malignancies. / Coccia, Peter Felix.

In: Seminars in Oncology, Vol. 4, No. 3, 01.12.1977, p. 287-296.

Research output: Contribution to journalReview article

@article{0fca10a2a267420ca8e2d30e634a303d,
title = "Characterization of the blast cell in childhood non-Hodgkin's lymphoproliferative malignancies",
abstract = "Studies of cytomorphology, cytochemistry, phagocytosis and surface membrane markers for T- and B-lymphocyte characteristics have led to the realization that the traditional separation of ALL and NHL is invalid. Patient characteristics, clinical presentation, distribution of disease at diagnosis, response to therapy, remission duration, sites of relapse and survival all appear to correlate better with characterization and classification by the type of blast cell identified rather than with presence or absence of bone marrow involvement at diagnosis. Clearly, leukemias and lymphomas with cytomorphologically and cytochemically distinctive Burkitt's tumor cells which have monoclonal IgM on their surface are the same disease. In addition many clinical similarities are present in these patients whether or not the bone marrow is involved. Likewise, patients with sheep erythrocyte positive blast cells have similar diseases whether or not the marrow is involved. Subtypes of surface marker negative ALL and NHL will certainly be defined when the studies described above are routinely performed. Morphologic and cytochemical subtypes are recognizable and studies with (T cell antigen) HTLA and HBLA antisera suggest that further subclassification is possible. Whether these differences will be clinically, prognostically, and therapeutically useful must await the test of time. Attempts to stage childhood ALL and NHL on the basis of expected prognosis will certainly benefit from the additional input of careful characterization of the blast cells in these disorders. Careful pretreatment staging of children with non-Hodgkin's lymphoproliferative malignancies will in the future lead to more specific and effective therapy and improved remission duration and survival. (111 references).",
author = "Coccia, {Peter Felix}",
year = "1977",
month = "12",
day = "1",
language = "English (US)",
volume = "4",
pages = "287--296",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Characterization of the blast cell in childhood non-Hodgkin's lymphoproliferative malignancies

AU - Coccia, Peter Felix

PY - 1977/12/1

Y1 - 1977/12/1

N2 - Studies of cytomorphology, cytochemistry, phagocytosis and surface membrane markers for T- and B-lymphocyte characteristics have led to the realization that the traditional separation of ALL and NHL is invalid. Patient characteristics, clinical presentation, distribution of disease at diagnosis, response to therapy, remission duration, sites of relapse and survival all appear to correlate better with characterization and classification by the type of blast cell identified rather than with presence or absence of bone marrow involvement at diagnosis. Clearly, leukemias and lymphomas with cytomorphologically and cytochemically distinctive Burkitt's tumor cells which have monoclonal IgM on their surface are the same disease. In addition many clinical similarities are present in these patients whether or not the bone marrow is involved. Likewise, patients with sheep erythrocyte positive blast cells have similar diseases whether or not the marrow is involved. Subtypes of surface marker negative ALL and NHL will certainly be defined when the studies described above are routinely performed. Morphologic and cytochemical subtypes are recognizable and studies with (T cell antigen) HTLA and HBLA antisera suggest that further subclassification is possible. Whether these differences will be clinically, prognostically, and therapeutically useful must await the test of time. Attempts to stage childhood ALL and NHL on the basis of expected prognosis will certainly benefit from the additional input of careful characterization of the blast cells in these disorders. Careful pretreatment staging of children with non-Hodgkin's lymphoproliferative malignancies will in the future lead to more specific and effective therapy and improved remission duration and survival. (111 references).

AB - Studies of cytomorphology, cytochemistry, phagocytosis and surface membrane markers for T- and B-lymphocyte characteristics have led to the realization that the traditional separation of ALL and NHL is invalid. Patient characteristics, clinical presentation, distribution of disease at diagnosis, response to therapy, remission duration, sites of relapse and survival all appear to correlate better with characterization and classification by the type of blast cell identified rather than with presence or absence of bone marrow involvement at diagnosis. Clearly, leukemias and lymphomas with cytomorphologically and cytochemically distinctive Burkitt's tumor cells which have monoclonal IgM on their surface are the same disease. In addition many clinical similarities are present in these patients whether or not the bone marrow is involved. Likewise, patients with sheep erythrocyte positive blast cells have similar diseases whether or not the marrow is involved. Subtypes of surface marker negative ALL and NHL will certainly be defined when the studies described above are routinely performed. Morphologic and cytochemical subtypes are recognizable and studies with (T cell antigen) HTLA and HBLA antisera suggest that further subclassification is possible. Whether these differences will be clinically, prognostically, and therapeutically useful must await the test of time. Attempts to stage childhood ALL and NHL on the basis of expected prognosis will certainly benefit from the additional input of careful characterization of the blast cells in these disorders. Careful pretreatment staging of children with non-Hodgkin's lymphoproliferative malignancies will in the future lead to more specific and effective therapy and improved remission duration and survival. (111 references).

UR - http://www.scopus.com/inward/record.url?scp=0017697009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017697009&partnerID=8YFLogxK

M3 - Review article

VL - 4

SP - 287

EP - 296

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 3

ER -